Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.
Winter
Jane N
JN
Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. j-winter@northwestern.edu
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D018951:Antigens, CD20; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods; D033581:Stem Cell Transplantation; D014182:Transplantation, Autologous; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan